Pimodivir - Johnson & Johnson Innovative Medicine
Alternative Names: JNJ-3872; JNJ-63623872; JNJ-872; VX 787Latest Information Update: 05 Nov 2023
At a glance
- Originator Vertex Pharmaceuticals
- Developer Janssen Pharmaceuticals; Vertex Pharmaceuticals
- Class Antivirals; Pyridines; Pyrimidines; Pyrroles; Small molecules
- Mechanism of Action Viral protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Influenza A virus infections
Most Recent Events
- 01 Oct 2023 Janssen Pharmaceuticals is now called Johnson & Johnson Innovative Medicine (Janssen Pharmaceuticals website, October 2023)
- 02 Sep 2020 Discontinued - Phase-I for Influenza A virus infections (In volunteers) in Belgium (IV)
- 02 Sep 2020 Discontinued - Phase-I for Influenza A virus infections (In volunteers) in Netherlands (PO)